Table 4. Tandutinib phase 1 experience:... | American Society of Hematology

Table 4.

Tandutinib phase 1 experience: selected drug-related adverse events by CTC grade

									Edema, grade
		Nausea, grade			Vomiting, grade			Diarrhea, grade					Periorbital			Peripheral
Dose level, mg twice daily	No. of patients	1	2	1	2	1	2	3	1	2	1	2
50	6	1	0	0	0	1	0	0	0	0	1	0
100	3	1	0	0	0	0	0	0	0	0	1	0
150	6	0	1	0	1	1	0	0	0	0	0	0
200	3	2	1	2	1	0	0	0	0	0	1	0
250	3	1	0	1	0	1	1	0	1	0	1	1
300	6	4	0	2	1	3	0	0	0	0	0	0
400	4	2	2	1	0	1	1	0	0	0	2	0
525	6	1	1	2	1	2	1	0	1	0	0	0
700	3	2	0	2	1	2	2	1	1	1	2	1
Total	40	14	5	10	5	11	5	1	3	1	8	2

									Edema, grade
		Nausea, grade			Vomiting, grade			Diarrhea, grade					Periorbital			Peripheral
Dose level, mg twice daily	No. of patients	1	2	1	2	1	2	3	1	2	1	2
50	6	1	0	0	0	1	0	0	0	0	1	0
100	3	1	0	0	0	0	0	0	0	0	1	0
150	6	0	1	0	1	1	0	0	0	0	0	0
200	3	2	1	2	1	0	0	0	0	0	1	0
250	3	1	0	1	0	1	1	0	1	0	1	1
300	6	4	0	2	1	3	0	0	0	0	0	0
400	4	2	2	1	0	1	1	0	0	0	2	0
525	6	1	1	2	1	2	1	0	1	0	0	0
700	3	2	0	2	1	2	2	1	1	1	2	1
Total	40	14	5	10	5	11	5	1	3	1	8	2

Values in the data field indicate number of patients. Note that a patient was counted once for each grade of the adverse events experienced.